Table 1.
Demographic and clinical variables.
| All (n = 26) | Cycling (n = 18) | Stretch (n = 8) | T Value or χ2 | p | |
|---|---|---|---|---|---|
| Age | 77.6 (6.9) | 76.8 (7.6) | 79.3 (5.5) | −0.81 | 0.423 |
| Sex (Female) | 9 (34.6) | 7 (38.9) | 2 (25.0) | 0.472 | 0.492 |
| Race/Ethnicity | 2.72 | 0.256 | |||
| non-Hispanic White | 24 (92.3) | 17 (94.4) | 7 (87.5) | ||
| Hispanic White | 1 (3.8) | 1 (5.5) | - | ||
| Black American | 1 (3.8) | - | 1 (12.5) | ||
| Education (years) | 15.4 (2.9) | 15.9 (3.2) | 14.5 (2.5) | 1.05 | 0.361 |
| APOE genotype | 2.88 | 0.224 | |||
| E2/E3 | 3.8% | 5.6% | 0% | ||
| E3/E4 | 42.3% | 33.3% | 62.5% | ||
| E2/E4 | 26.9% | 33.3% | 12.5% | ||
| E4/E4 | 26.9% | 27.8% | 25.0% | ||
| BMI | 27.7 (4.4) | 26.8 (4.1) | 29.7 (4.7) | −1.58 | 0.126 |
| MMSE | 21.6 (3.3) | 21.3 (3.7) | 22.3 (2.3) | −0.96 | 0.348 |
| CVD | 6 (23.1) | 4 (22.2) | 2 (25.0) | FET | 0.651 |
| Beta blocker | 1 (3.8) | - | 1 (12.5) | FET | 0.308 |
| AD medications | 17 (65.4) | 11 (61.1) | 6 (75.0) | FET | 0.413 |
| VO2Peak (mL/kg/min) | 18.3 (4.6) | 18.4 (5.0) | 18.0 (3.8) | 0.20 | 0.842 |
APOE; apolipoprotein E: BMI; body mass index: MMSE; mini mental state examination: CVD; cardiovascular disease: AD; Alzheimer’s dementia: VO2Peak; peak oxygen consumption: FET: Fischer exact test.